The association of surgical resection of the intact primary in women with de novo stage IV breast cancer with survival has received a great deal of attention in the past decade; this issue of the Annals of Surgical Oncology contains the fourth meta-analysis/systematic review of approximately one dozen retrospective studies examining this association.
The association of surgical resection of the intact primary in women with de novo stage IV breast cancer with survival has received a great deal of attention in the past decade; this issue of the Annals of Surgical Oncology contains the fourth meta-analysis/systematic review of approximately one dozen retrospective studies examining this association. [1] [2] [3] The reasons that this question is of interest biologically and of practical importance to our patients are well recapitulated by Harris and colleagues and have been discussed extensively elsewhere. 4 The fact that a fourth analysis of the same data is considered sufficiently interesting and novel for publication in the Annals illustrates the high level of interest that has emerged over the past decade in the question of primary tumor resection in Stage IV solid tumors. Harris et al. provide a summary estimated hazard ratio of 0.69 (95 % confidence interval (CI) 0.54-0.88) pooled from ten studies that favors surgical resection of the primary tumor, acknowledge the potential biases, and conclude their abstract with the statement that, ''In the absence of robust evidence, this meta-analysis provides evidence base for primary resection in the setting of stage IV breast cancer for appropriately selected patients.'' The devil, of course, is always in the details, and the authors offer no specific recommendations as to what constitutes appropriate selection. Nor can they. The only hint regarding surgical selection of patients in their analysis comes from a lack of association of benefit with large primary tumors and large number of metastatic sites, but they wisely ignore this trend in their Discussion. In fact, another recent meta-analysis where the use of a variable effects meta-regression model was specified, found no difference in the apparent benefit of surgery based on number of sites of disease, rate of bone or visceral metastasis, type of surgery, margin status, and median age. 3 (Notably, Harris et al. do not tell us how much betweenstudy heterogeneity they observed, and whether a random or a fixed-effects model was used.) The authors of this and three similar analyses (one meta-analysis and two systematic reviews) therefore are uniformly circumspect in not recommending a basis for patient selection for surgery in any of their Discussions.
The larger question clearly relates to what we can learn from repeated attempts to pool and analyse the same biased, retrospective data. All authors recognize the biases: women receiving surgery are younger, with better access to care, healthier, more likely to have a lower metastatic burden (to the extent that this is captured), and are more likely to have estrogen receptor-positive disease. The biases themselves have not been meta-analysed, but it is a reasonable wager that they would pass a test of homogeneity. As any primer on clinical evidence informs us, statistical adjustment for biases may allow alleviation of those that we recognize (and hopefully can measure reproducibly) but leaves open the yawning pit of biases that we do not recognize or cannot measure. In other words, the criteria that guide Level I evidence are based on sound principles that editors, reviewers, and readers must remember when encountering reports of the same biased data in new garb. Authors must be challenged when they state in the Abstract (likely to be viewed by large numbers of practitioners and possibly patients who will not read the paper) what they cannot support in the manuscript.
As we work through the flood of publications (rather than data) on this topic, it is worthwhile to pause to consider the harm that may accrue from primary site local therapy in the setting of what is almost certainly fatal distant disease. The morbidity of tumor resection, mastectomy, axillary surgery, even radiotherapy, although tolerable when cure is the goal, may add to the burden of suffering of a woman in her last few years of life. The interruptions of therapy that may be necessitated by the use of local therapy could have an adverse effect on the control of distant disease. Women who see themselves undergoing local treatment that is similar to their sisters with early disease are increasingly raising issues, such as reconstruction and contralateral mastectomy; interventions that may be difficult to deny and have significantly larger potential for harm than mere resection of a tumor. Finally, there is the financial cost, both systemic and individual, in a group of patients who may be stretching the limits of their insurance coverage and resources with the costs of systemic therapy, imaging, and all that is entailed therewith.
The question at hand will be answered within the next few years. Its importance is illustrated by the six groups of investigators in three continents who have worked to initiate randomized trials (Table 1) . Across these trials, there is enough homogeneity of design that preplanned pooled analyses (or even meta-analyses) will likely identify even small benefits associated with local therapy for the intact primary. Three of the six trials specify local therapy plans that mirror those in the nonmetastatic setting, including radiotherapy; all specify the use of systemic therapy (before local therapy in three and following surgery in three); and five of six have the primary endpoint of overall survival.
With the completion of these trials, more than 2,000 women will have been treated in a prospectively planned, randomized fashion, and we will be able to reach solid conclusions regarding the role of locoregional therapy, its extent, and its timing, in women with overt metastases. The variations in design will allow some assessment of the value of surgery alone versus surgery plus radiotherapy; and at least two of the trials have specific quality of life (QOL)-related endpoints. This last is of course of paramount importance, because there are QOL hazards in both directions: the QOL impact of locoregional therapy (particularly axillary surgery and radiotherapy) must be considered against the QOL costs of uncontrolled local disease. To weigh these hazards, it is necessary to know how frequently the primary tumor progresses to uncontrolled or symptomatic local disease if primary site therapy consists only of systemic agents (the traditional standard in Stage IV disease) versus the addition of local therapy for the primary site. The retrospective studies published so far offer no guidance in this regard, with the exception of two small series: one with 20 patients, 8 and the other with 111 patients. 9 Both suggest value of local therapy in maintaining local control but are subject to the same biases as the studies reporting survival outcomes. A prospective registry study has completed accrual with 110 patients and will add more interpretable data in this regard (principal investigator, TA King), but the fact remains that systemic therapy does control local disease, and unless we show that local therapy maintains local control more effectively than systemic therapy in a sufficient fraction of Stage IV patients, we cannot in good conscience offer resection of the intact primary unless it progresses while distant disease is well-controlled.
At the moment therefore, when faced with the patient with distant metastases and an intact primary tumor, if a clinical trial is unavailable or declined, what should we advise? Attempts to select based on disease biology or burden are not supported by existing data (only one small study suggests lack of benefit of surgery in women with triple negative tumors 10 ). The only selection that seems reasonable is the presence of disease that is responsive to systemic agents. For the patient who has not initiated systemic therapy, that must be the first step; for the patient receiving systemic therapy and responding well at all sites, continuation of effective therapy is the most reasonable data-based choice; for the patient whose tumor is wellcontrolled at distant sites, but progressing locally, local therapy can be considered, although a path will need to be found through the thorny issues of whether or not to dissect the axilla, offer reexcision for positive margins, offer radiotherapy, advise for or against postmastectomy reconstruction, etc. Hopefully all will agree that we must advise such a patient against contralateral prophylactic mastectomy. The fact that some women are seeking, and (anecdotally) receiving, contralateral mastectomy despite the presence of distant metastases illustrates the slippery path that we embark upon if unbiased empirical evidence and clear concepts do not guide our practice. 
